--- title: "Independent Chairman of AstraZeneca Michel Demare Buys 25% More Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/299275302.md" description: "AstraZeneca's Independent Chairman, Michel Demare, purchased UK£303k worth of shares at UK£121 per share, increasing his holding by 25%. This recent buy contrasts with a net insider selling trend over the past year, where insiders sold significantly more than they bought. While the Chairman's purchase signals confidence, overall insider ownership remains low at 0.04%, leading to cautious long-term assessments despite alignment with shareholder interests." datetime: "2026-09-17T06:12:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299275302.md) - [en](https://longbridge.com/en/news/299275302.md) - [zh-HK](https://longbridge.com/zh-HK/news/299275302.md) generator: "portal-rs" --- # Independent Chairman of AstraZeneca Michel Demare Buys 25% More Shares Investors who take an interest in **AstraZeneca PLC** (LON:AZN) should definitely note that the Independent Chairman, Michel Demare, recently paid UK£121 per share to buy UK£303k worth of the stock. That's a very decent purchase to our minds and it grew their holding by a solid 25%. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. ## AstraZeneca Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider sale was by the insider, Mani Sharma, for UK£1.6m worth of shares, at about UK£138 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (UK£121). So it is hard to draw any strong conclusion from it. Over the last year, we can see that insiders have bought 2.52k shares worth UK£305k. On the other hand they divested 12.19k shares, for UK£1.7m. All up, insiders sold more shares in AstraZeneca than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for AstraZeneca If you like to buy stocks that insiders are buying, rather than selling, then you might just love this **free** list of companies. (Hint: Most of them are flying under the radar). ## Insider Ownership Of AstraZeneca Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. AstraZeneca insiders own 0.04% of the company, currently worth about UK£75m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. ## So What Does This Data Suggest About AstraZeneca Insiders? It's certainly positive to see the recent insider purchases. However, the longer term transactions are not so encouraging. While recent transactions indicate confidence in AstraZeneca, insiders don't own enough of the company to overcome our cautiousness about the longer term transactions. Overall they seem reasonably aligned. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To assist with this, we've discovered **1 warning sign** that you should run your eye over to get a better picture of AstraZeneca. Of course, **you might find a fantastic investment by looking elsewhere.** So take a peek at this **free** list of interesting companies. *For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.* ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) ## Related News & Research - [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md) - [AstraZeneca CFO Sarin gains 73 shares from 2021 performance share plan dividend equivalents](https://longbridge.com/en/news/299064766.md) - [AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500](https://longbridge.com/en/news/298918563.md) - [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md) - [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**